This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Teva Pharmaceutical Industries Ltd.

Drug Names(s): MicroDose Inhaled Insulin

Description: Vectura, through its joint venture with MicroDose Technologies, QDose Limited, has developed a rapid acting, dry powder, insulin formulation designed to give highly efficient delivery from the MicroDose Electronic Inhaler.

Deal Structure: Bristol-Myers Squibb, MicroDose, and Quadrant
On September 15, 2003, Bristol-Myers Squibb signed an agreement with QDose, a joint venture between MicroDose Technologies and Quadrant Drug Delivery of the UK, for an inhaled insulin product. Under the terms of the latest agreement, BMS gains worldwide exclusive rights to the inhaled insulin and will take the lead on development, manufacturing and commercialisation of the licensed product. BMS will pay a $1 million (887,000) upfront payment to QDose and will pay an additional $29 million in milestone payments based on the achievement of certain development and regulatory events, as well as royalties on any eventual sales.

Innovata, MicroDose, and Bristol-Myers Squibb
In December 2005, Innovata announced the restructuring of the agreement between QDose, its joint venture with MicroDose Technologies and Bristol-Myers Squibb Company relating to fast acting inhaled insulin. Bristol-Myers Squibb has decided to...See full deal structure in Biomedtracker

Partners: Vectura Group Bristol-Myers Squibb Company

QDose News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug